Evolving Market Trends In The Endocrine Peptide Test Industry: Advancements in Immunoassay Testing Systems for Endocrine Peptide Testing

The Endocrine Peptide Test Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Expected Endocrine Peptide Test Market Size During the Forecast Period?
The endocrine peptide test market size has grown strongly in recent years. It will grow from $9.11 billion in 2024 to $9.97 billion in 2025 at a compound annual growth rate (CAGR) of 9.5%. The growth in the historic period can be attributed to increasing government spending, rising prevalence of diabetes, decreasing level of immunity in people across the world, high risk of contracting any chronic diseases, and rising government initiatives.

The endocrine peptide test market is expected to grow significantly, reaching $14.22 billion by 2029, with a CAGR of 9.3%. This growth is fueled by the increasing demand for endocrine peptide tests, growth in research and development, rising lifestyle diseases, an aging population, and the increasing prevalence of diabetes. Key trends include advancements in endocrine testing methods, progress in product technologies, an increase in R&D activities to develop new testing solutions, a growing number of product approvals, and a shift towards preventive healthcare.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16675

What Are the High-Growth Segments in the Endocrine Peptide Test Market?
The endocrine peptide test market covered in this report is segmented -

1) By Test-Type: Dehydroepiandrosterone Sulphate, Progesterone, Luteinizing Hormone, Thyroid Prolactin, Oestradiol, Human Chorionic Gonadotropin, Thyroid-Stimulating Hormone, Other Test-Types
2) By Technology: Mass Spectroscopy, Immunoassay, Chromatography, Nucleic Acid Based, Other Technologies
3) By End-User: Clinics, Healthcare Centers, Hospitals, Commercial Laboratories

Subsegments:
1) By Dehydroepiandrosterone Sulphate (DHEA-S): Immunoassay Tests, Enzyme-Linked Immunosorbent Assay (ELISA), Radioimmunoassay (RIA)
2) By Progesterone: Immunoassay Tests, Chemiluminescence Assays, ELISA Tests
3) By Luteinizing Hormone (LH): Immunoassay Tests, Enzyme Immunoassay (EIA), Radioimmunoassay (RIA)
4) By Thyroid Prolactin: Immunoassay Tests, Chemiluminescence Assays, Radioimmunoassay (RIA)
5) By Oestradiol: Immunoassay Tests, Enzyme-Linked Immunosorbent Assay (ELISA), Radioimmunoassay (RIA)
6) By Human Chorionic Gonadotropin (hCG): Immunoassay Tests, Chemiluminescence Assays, Enzyme Immunoassay (EIA)
7) By Thyroid-Stimulating Hormone (TSH): Immunoassay Tests, Radioimmunoassay (RIA), Enzyme-Linked Immunosorbent Assay (ELISA)
8) Other Test-Types: Cortisol, Insulin, Growth Hormone (GH), Parathyroid Hormone (PTH)

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16675&type=smp

What Key Drivers Are Expected to Influence Future Endocrine Peptide Test Market Growth?
The rising prevalence of diabetes is expected to drive the growth of the endocrine peptide test market moving forward. Diabetes is a group of diseases that cause high blood sugar (glucose) levels. The increasing prevalence of diabetes is attributed to unhealthy diets, sedentary lifestyles, genetic factors, and an aging population. Endocrine peptide tests, such as hemoglobin A1c, fasting plasma glucose, and C-peptide tests, are used to diagnose diabetes, monitor glucose levels, and assess insulin production and sensitivity. For instance, in June 2024, the UK's National Health Service (NHS) reported a significant increase in the number of individuals under 40 diagnosed with diabetes, rising from 173,166 in 2022 to 216,440 in 2023. This surge underscores the concerning trend of increasing diabetes rates among younger people. Therefore, the growing prevalence of diabetes is driving the endocrine peptide test market.

Which Companies Hold the Largest Share Across Different Endocrine Peptide Test Market Segments?
Major companies operating in the endocrine peptide test market are Siemens AG, F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Merck KGaA, Becton dic*kinson and Company, Laboratory Corporation of America Holdings (LabCorp), Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., bioMérieux SA, Bio-Rad Laboratories Inc., DiaSorin S.p.A., Sciex, Bio-Techne Corporation, Invitae Corporation, ARUP Laboratories, Genova Diagnostics, Boston Heart Diagnostics Corporation, Immunodiagnostic Systems Ltd., Mayo Clinic Laboratories

What Are the Major Trends Shaping the Endocrine Peptide Test Market?
Top firms involved in the endocrine peptide test market look to immunoassay testing systems to enhance the precision, sensitivity, and swiftness of endocrine peptide examinations. These systems make use of antibodies to recognize and quantify specific peptides found in blood or urine, supplying critical data about hormone levels and endocrine function to healthcare practitioners. For example, in July 2023, Siemens Healthineers, a healthcare service provider based in Germany, unveiled the Atellica CI Analyzer, a compact immunoassay and clinical chemistry testing device. It is used, among other things, for endocrine peptide assays. The analyzer comes with a reproductive endocrinology menu which includes anti-Mullerian hormone (AMH) for ovarian reserve assessment and sFlt-1 and PlGF (placental growth factor), which are useful in predicting preeclampsia. The Atellica CI Analyzer is engineered to yield reliable results swiftly and consistently, being able to perform up to 1000 tests within an hour. It allows for efficiency and adaptability in workflow, which aids laboratories in addressing changing testing requirements.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/endocrine-peptide-test-global-market-report

What Are the Emerging Geographies for The Endocrine Peptide Test Market Growth?
North America was the largest region in the endocrine peptide test market in 2024. The regions covered in the endocrine peptide test market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Endocrine Peptide Test Market?
2. What is the CAGR expected in the Endocrine Peptide Test Market?
3. What Are the Key Innovations Transforming the Endocrine Peptide Test Industry?
4. Which Region Is Leading the Endocrine Peptide Test Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.